Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Gaughran

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Aripiprazole Once-Monthly is a Cost-Effective Therapeutic Option in the Maintenance Treatment of Schizophrenia: Results from a Markov ModelC Sapin, M J Tempest, F Gaughran, et al.
Schizophrenia Research|March 28, 1998
Increased soluble interleukin 2 receptor levels in schizophreniaF Gaughran, E O'Neill, M Cole, et al.
The British Journal of Psychiatry : the Journal of Mental Science|July 3, 2007
Cost-effectiveness of first- v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapyL M Davies, S Lewis, P B Jones, et al.
Journal of Psychiatric and Mental Health Nursing|May 17, 2013
Provision of health promotion programmes to people with serious mental illness: a mapping exercise of four South London boroughsC O'Brien, P Gardner-Sood, S K Corlett, et al.
BMC Psychiatry|March 23, 2016
Clinical correlates of vitamin D deficiency in established psychosisJ Lally, P Gardner-Sood, M Firdosi, et al.
Acta Psychiatrica Scandinavica|September 10, 2014
The practical management of refractory schizophrenia--the Maudsley Treatment REview and Assessment Team service approachK Beck, R McCutcheon, M A P Bloomfield, et al.
Social Psychiatry and Psychiatric Epidemiology|February 6, 2016
Ethnicity and cardiovascular health inequalities in people with severe mental illnesses: protocol for the E-CHASM studyJ Das-Munshi, M Ashworth, F Gaughran, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|December 16, 2016
Type 2 diabetes mellitus in people with severe mental illness: inequalities by ethnicity and age. Cross-sectional analysis of 588 408 records from the UKJ Das-Munshi, M Ashworth, M E Dewey, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists|December 27, 2014
Reasons for cannabis use in first-episode psychosis: does strength of endorsement change over 12 months?A Kolliakou, D Castle, H Sallis, et al.
Psychological Medicine|September 19, 2015
Impact of childhood adversities on specific symptom dimensions in first-episode psychosisO Ajnakina, A Trotta, E Oakley-Hannibal, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Aripiprazole Once-Monthly is a Cost-Effective Therapeutic Option in the Maintenance Treatment of Schizophrenia: Results from a Markov ModelC Sapin, M J Tempest, F Gaughran, et al.
Schizophrenia Research|March 28, 1998
Increased soluble interleukin 2 receptor levels in schizophreniaF Gaughran, E O'Neill, M Cole, et al.
The British Journal of Psychiatry : the Journal of Mental Science|July 3, 2007
Cost-effectiveness of first- v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapyL M Davies, S Lewis, P B Jones, et al.
Journal of Psychiatric and Mental Health Nursing|May 17, 2013
Provision of health promotion programmes to people with serious mental illness: a mapping exercise of four South London boroughsC O'Brien, P Gardner-Sood, S K Corlett, et al.
BMC Psychiatry|March 23, 2016
Clinical correlates of vitamin D deficiency in established psychosisJ Lally, P Gardner-Sood, M Firdosi, et al.
Acta Psychiatrica Scandinavica|September 10, 2014
The practical management of refractory schizophrenia--the Maudsley Treatment REview and Assessment Team service approachK Beck, R McCutcheon, M A P Bloomfield, et al.
Social Psychiatry and Psychiatric Epidemiology|February 6, 2016
Ethnicity and cardiovascular health inequalities in people with severe mental illnesses: protocol for the E-CHASM studyJ Das-Munshi, M Ashworth, F Gaughran, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|December 16, 2016
Type 2 diabetes mellitus in people with severe mental illness: inequalities by ethnicity and age. Cross-sectional analysis of 588 408 records from the UKJ Das-Munshi, M Ashworth, M E Dewey, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists|December 27, 2014
Reasons for cannabis use in first-episode psychosis: does strength of endorsement change over 12 months?A Kolliakou, D Castle, H Sallis, et al.
Psychological Medicine|September 19, 2015
Impact of childhood adversities on specific symptom dimensions in first-episode psychosisO Ajnakina, A Trotta, E Oakley-Hannibal, et al.
Pageof 3